Particles Comprising T-Cell Receptor Binding Molecules and Slamf7 Molecules

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes specialized particles that are engineered to present two types of molecules on their surface: one that can bind to T-cell receptors (such as MHC molecules) and another that displays the extracellular domain of SLAMF7. When these particles come into contact with T-cells, they can specifically activate and enhance the function of cytotoxic CD8+ T-cells, which are essential for targeting cancerous or infected cells. The particles can be used in medicines to treat cancer, infections, or inflammation, can serve as vaccines, and can be used to expand and enrich T-cells outside the body for adoptive cell therapies.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of cancers by enhancing the patient’s own immune response against tumors.
• Therapy for viral, bacterial, or fungal infections, including emerging diseases such as COVID-19.
• Immunotherapy for inflammatory diseases or chronic inflammation.
• Development of vaccines targeting specific antigens.
• Ex-vivo activation and expansion of T-cells for adoptive T-cell transfer therapies.
• Diagnostic tools for monitoring T-cell activation and immune responses in research or clinical settings.
• Prognosis or disease status determination by detecting SLAMF7-expressing T-cells.
• Combining with other drugs (e.g., checkpoint inhibitors, chemotherapeutics) for synergistic therapies.
• Prophylactic immunization to prevent cancer or infections.

BenefitsContent extracted from patent full text and abstract with AI.

• Highly targeted activation of cytotoxic T-cells, reducing harm to healthy tissues and minimizing side effects.
• Potential for personalized immunotherapies based on patient-specific antigens or diseases.
• Capable of inducing robust and lasting immunologic memory, offering protection against recurrence or metastasis.
• Enables activation and proliferation of T-cells even against weakly immunogenic antigens, broadening therapy effectiveness.
• Switchable (can be deactivated if necessary), improving therapy safety control.
• Usable both in vivo (direct therapeutic application) and ex vivo (cell expansion for reinfusion), increasing flexibility.
• May reduce or eliminate the need for immunoadjuvants, limiting potential adjuvant-related side effects.
• Can be used as a vaccine platform against cancer or infectious diseases, addressing both therapy and prevention.
• Facilitates precise monitoring and detection of T-cell immune responses in research and diagnostics.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a particle comprising one or more molecules capable of binding a T-cell receptor and one or more molecules comprising an extracellular domain of SLAMF7. Further, the present invention relates to the particle or a composition comprising a plurality of particles for use as medicament, in particular for use in the treatment of cancer, an infection, or an inflammation. The present invention also relates to a combination comprising the particle or the composition and a drug different from the particle or composition for use as medicament, in particular for use in the treatment of cancer, an infection, or an inflammation. Additionally, the invention relates to a kit comprising the particle or composition.